473 related articles for article (PubMed ID: 23739841)
21. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.
Zikria JC; Ansell J
Curr Opin Hematol; 2009 Sep; 16(5):347-56. PubMed ID: 19550318
[TBL] [Abstract][Full Text] [Related]
22. New anticoagulants for the prevention of stroke in atrial fibrillation.
Höchtl T; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):47-53. PubMed ID: 21883447
[TBL] [Abstract][Full Text] [Related]
23. Factor XI and contact activation as targets for antithrombotic therapy.
Gailani D; Bane CE; Gruber A
J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Schellong S
Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
[TBL] [Abstract][Full Text] [Related]
25. A new era for oral anticoagulation? Old and new anticoagulant drugs.
Verhamme P; Verhaeghe R
Acta Cardiol; 2007 Apr; 62(2):189-98. PubMed ID: 17536609
[TBL] [Abstract][Full Text] [Related]
26. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants.
Weitz JI; Fredenburgh JC
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):304-310. PubMed ID: 29269514
[TBL] [Abstract][Full Text] [Related]
27. Factor XI as a Therapeutic Target.
Gailani D; Gruber A
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
[TBL] [Abstract][Full Text] [Related]
28. Direct thrombin inhibitors for anticoagulation.
Nutescu EA; Wittkowsky AK
Ann Pharmacother; 2004 Jan; 38(1):99-109. PubMed ID: 14742803
[TBL] [Abstract][Full Text] [Related]
29. [Rivaroxaban: mode of action].
Drouet L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
[TBL] [Abstract][Full Text] [Related]
30. Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation.
Székely O; Borgi M; Lip GYH
Expert Opin Emerg Drugs; 2019 Mar; 24(1):55-61. PubMed ID: 30845846
[TBL] [Abstract][Full Text] [Related]
31. Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
Zikria J; Ansell J
Discov Med; 2009 Dec; 8(43):196-203. PubMed ID: 20040270
[TBL] [Abstract][Full Text] [Related]
32. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
Apostolakis S; Lip GY
Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
[TBL] [Abstract][Full Text] [Related]
33. [Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors].
Sié P; Samama CM; Godier A; Rosencher N; Steib A; Llau JV; van der Linden P; Pernod G; Lecompte T; Gouin-Thibault I; Albaladejo P
Ann Fr Anesth Reanim; 2011 Sep; 30(9):645-50. PubMed ID: 21820844
[TBL] [Abstract][Full Text] [Related]
34. Orally active direct thrombin inhibitors.
Weitz J
Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
[TBL] [Abstract][Full Text] [Related]
35. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
Lämmle B; Griffin JH
Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
[TBL] [Abstract][Full Text] [Related]
36. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.
Ahrens I; Peter K; Lip GY; Bode C
Discov Med; 2012 Jun; 13(73):445-50. PubMed ID: 22742650
[TBL] [Abstract][Full Text] [Related]
37. Novel anticoagulants and the future of anticoagulation.
Garcia D
Thromb Res; 2009; 123 Suppl 4():S50-5. PubMed ID: 19303505
[TBL] [Abstract][Full Text] [Related]
38. Disadvantages of VKA and requirements for novel anticoagulants.
Shameem R; Ansell J
Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
[TBL] [Abstract][Full Text] [Related]
39. New anticoagulants: from bench to bedside.
Haas S; Schellong S
Hamostaseologie; 2007 Feb; 27(1):41-7. PubMed ID: 17279275
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
